Chauche Thierry 4

What Happened
Thierry Chauche, Chief Financial Officer of Sagimet Biosciences, received a derivative equity award for 50,000 shares on May 28, 2026. The reported acquisition price is $0.00 (total reported value $0), and the award is structured as an option-like grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-28; Form 4 filed: 2026-06-01 (timely filing).
• Reported transaction type: Grant / award (derivative) of 50,000 shares; reported price $0.00.
• Vesting: The underlying shares/options vest and become exercisable in 48 equal monthly installments beginning May 28, 2026 (footnote disclosed).
• Shares owned after transaction: Not specified in the provided filing details.
• No indication this was a sale, purchase for cash, 10b5-1 plan, or tax-withholding event in the disclosure.

Context
This was a compensation-style grant (a derivative award) that vests over four years, meaning Chauche does not immediately receive freely tradable shares; the award is intended to vest with continued service. Such grants are common for executive retention and do not represent an open-market buy or sell.